DNLI · Company research
Denali Therapeutics Inc. (DNLI): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) Stock Price, News, Quote & History - Yahoo! Finance Canada | Denali Therapeutics Inc. (DNLI) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Denali Therapeutics Inc. (DNLI) stock price, news, quote and history - Yahoo Finance UK | Denali Therapeutics Inc. (DNLI) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 15, 2026 | neutral | 0 | 0.6 |
| Denali Therapeutics Inc. (DNLI) latest stock news and headlines - Yahoo Finance UK | Denali Therapeutics Inc. (DNLI) latest stock news and headlines Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 14, 2026 | neutral | 0 | 0.6 |
| Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? | Ultragenyx Pharmaceutical reported $350 million in first-half 2026 revenues, up 14% year-over-year, driven by Crysvita ($249M) and strong growth in Evkeeza (up 56%). The company received FDA approvals for two new gene therapies—Genglycos and Fayuvi—and sold a priority review voucher for $210 million. However, RARE stock has underperformed, declining 35.1% year-to-date, and faces competition from Amgen and Denali Therapeutics. The company carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.333 | 1 |
| Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? | Ultragenyx Pharmaceutical reported $350 million in first-half 2026 revenues, up 14% year-over-year, driven by Crysvita ($249M) and strong growth in Evkeeza (up 56%). The company received FDA approvals for two new gene therapies—Genglycos and Fayuvi—and sold a priority review voucher for $210 million. However, RARE stock has underperformed, declining 35.1% year-to-date, and faces competition from Amgen and Denali Therapeutics. The company carries a Zacks Rank #3 (Hold) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.333 | 1 |
| Denali Therapeutics (NasdaqGS:DNLI) Stock Forecast & Analyst Predictions - Simply Wall Street | Denali Therapeutics (NasdaqGS:DNLI) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| DNLI stock falls 1.77 percent as AVLAYAH launch enters a test - AD HOC NEWS | DNLI stock falls 1.77 percent as AVLAYAH launch enters a test AD HOC NEWS | View source ↗ | AD HOC NEWS | Oct 6, 2026 | neutral | 0 | 0.6 |
| Director Nancy Thornberry plans Denali (NASDAQ: DNLI) stock sale - Stock Titan | Director Nancy Thornberry plans Denali (NASDAQ: DNLI) stock sale Stock Titan | View source ↗ | Stock Titan | Sep 2, 2026 | neutral | 0 | 0.6 |
| DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? - Yahoo Finance | DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 20, 2026 | neutral | 0 | 0.6 |
| Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI) - Seeking Alpha | Denali Therapeutics: Bullish On AVLAYAH And Their Prospects (NASDAQ:DNLI) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 19, 2026 | neutral | 0 | 0.6 |
| Will AVLAYAH’s Launch And Cash Windfall Reshape Denali Therapeutics' (DNLI) Investment Narrative - Simply Wall Street | Will AVLAYAH’s Launch And Cash Windfall Reshape Denali Therapeutics' (DNLI) Investment Narrative Simply Wall Street | View source ↗ | Simply Wall Street | Aug 15, 2026 | neutral | 0 | 0.6 |
| Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey? - Yahoo Finance | Denali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 22, 2026 | neutral | 0 | 0.6 |
| Will Recent Setbacks Impact Growth Prospects of DNLI Stock? - Yahoo Finance | Will Recent Setbacks Impact Growth Prospects of DNLI Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 15, 2026 | neutral | 0 | 0.6 |
| Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s - Stock Titan | Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s Stock Titan | View source ↗ | Stock Titan | Jul 9, 2026 | neutral | 0 | 0.6 |
| DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? - Yahoo Finance | DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 8, 2026 | neutral | 0 | 0.6 |
| DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? - TradingView | DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? TradingView | View source ↗ | TradingView | Jul 8, 2026 | neutral | 0 | 0.6 |
| DNLI Forecast — Price Target — Prediction for 2027 - TradingView | DNLI Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos - Yahoo Finance | Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos Yahoo Finance | View source ↗ | Yahoo Finance | Jun 1, 2026 | neutral | 0 | 0.6 |
| BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Stocktwits | BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial Stocktwits | View source ↗ | Stocktwits | May 21, 2026 | neutral | 0 | 0.6 |
| DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock? - Yahoo Finance | DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Apr 17, 2026 | neutral | 0 | 0.6 |
| $DNLI stock is up 7% today. Here's what we see in our data. - Quiver Quantitative | $DNLI stock is up 7% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Mar 9, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.